DEND syndrome (developmental delay, epilepsy, and neonatal diabetes mellitus) is a dominant disorder and a special form of permanent neonatal diabetes mellitus (PNDM) caused by specific KCNJ11 mutations. It is characterized by additional neurological symptoms as delayed cognitive development and epilepsy.
Permanent neonatal diabetes mellitus | ||||
ABCC8 | ||||
Developmental delay, epilepsy, and neonatal diabetes | ||||
KCNJ11 | ||||
GCK | ||||
INS | ||||
KCNJ11 | ||||
Phosphoribosylpyrophosphate synthetase superactivity | ||||
Wolcott-Rallison syndrome | ||||
1. |
Støy J et al. (2007) Insulin gene mutations as a cause of permanent neonatal diabetes. |
2. |
Arthur EI et al. () Transient neonatal diabetes mellitus in a child with invdup(6)(q22q23) of paternal origin. |
3. |
Edghill EL et al. (2007) Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. |
4. |
Stanik J et al. (2007) Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. |
5. |
Pearson ER et al. (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. |
6. |
Zung A et al. (2004) Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. |
7. |
Gloyn AL et al. (2002) Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. |
8. |
None (2000) Neonatal diabetes: new insights into aetiology and implications. |
10. |
Della Manna T et al. (2008) Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene. |
11. |
Koster JC et al. (2008) DEND mutation in Kir6.2 (KCNJ11) reveals a flexible N-terminal region critical for ATP-sensing of the KATP channel. |
12. |
Slingerland AS et al. (2008) Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. |
13. |
Koster JC et al. (2008) The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. |
14. |
Mlynarski W et al. (2007) Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. |
16. |
Shimomura K et al. (2007) A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. |
17. |
Masia R et al. (2007) An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. |
18. |
Gloyn AL et al. (2006) KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. |
19. |
Proks P et al. (2005) A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. |
20. |
Massa O et al. (2005) KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. |
21. |
Gloyn AL et al. (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. |
22. |
Babenko AP et al. (2006) Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. |
23. |
Proks P et al. (2006) A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. |
24. |
Suzuki S et al. (2007) Molecular basis of neonatal diabetes in Japanese patients. |
25. |
Colombo C et al. (2008) Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. |
28. |
Njølstad PR et al. (2001) Neonatal diabetes mellitus due to complete glucokinase deficiency. |
29. |
OMIM.ORG article Omim 606176 |
30. |
Orphanet article Orphanet ID 79134 |